The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Pre-Filled Syringes Market (2nd Edition), 2014 - 2024

  • Lowest Price Guaranteed From USD 1,899

  • Published
    July 2014

  • Pages
    230

  • View Count
    7026

Example Insights

An updated edition is available at the following link 

View 5th edition

  1. The global prefilled syringes market is likely to grow at a compounded annual growth rate (CAGR) of 11.3% between 2013 to 2024. By 2024, we expect the market to achieve sales of around 12.4 billion prefilled syringes.
  2. Vaccines, diluent and flush syringes are likely to be some of the key growth areas. The emergence of biologics will be a major growth driver; growth in the long-term will be fuelled by pipeline drugs and the rising adoption in developing markets.
  3. Increasing number of suppliers now provide ready to fill/ sterile prefilled syringes, which make up more than 80% of the prefilled syringes market. The integration of prefilled syringes with advanced delivery systems such as pen and autoinjectors will aid in gaining wider adoption.
  4. Developed markets of the US and EU together accounted for 80% of the prefilled syringes market in 2013. With the increasing adoption in China and rest of the world markets, this domination is likely to decline; by 2024, we expect the share of US and EU markets to slip to ~60%.
  5. The market is highly consolidated and is currently dominated by key global players such as Becton Dickinson, Gerresheimer, MGlas AG, SCHOTT and Nuova Ompi. Other companies, which are relatively new entrants (e.g. West Pharmaceutical Services, Unilife and Vetter Pharma) are likely to foster more innovation.
  6. Many regional players, especially in China, Japan and other Asian economies, have also recently surfaced to exploit the opportunity offered by large home consumer markets.

Overview

Prefilled syringes are gaining strong acceptance in the market as drug delivery systems for injectable drugs. They have become a preferred device for parenteral administration of drugs, mainly used for treatment of chronic conditions requiring patients to self-administer medication several times a week.

The origins of these syringes can be traced back to early 1980s when Sanofi and Rhone Poulenc-Rorer (Sanofi-Aventis) introduced syringes as drug delivery devices for heparins in Europe. Prefilled syringes were introduced initially as just a niche market product and their applications were limited to a few vaccines and anticoagulant products. Now they have been around for more than two decades and are used in all major therapeutic classes for injectable drug formulations. Owing to their numerous benefits over conventional delivery systems, prefilled syringes have become indispensable in the medical field. This is evident from our research during which we identified a large number of instances where prefilled syringes are being used to administer vaccines, anticoagulants, multiple sclerosis drugs, anti-arthritic drugs, anti-anaemic drugs and drugs from other classes. In addition, prefilled diluent syringes and flush syringes are also increasingly finding wider adoption. With pharma companies viewing prefilled syringes as a potent life cycle management tool, the pipeline is rich and growing rapidly.

The rising demand has also driven the manufacturers to introduce improvements in technology related to the material of prefilled syringes and lubrication (to reduce leachables and extractables). These developments will aid an increasing number of biologic drugs to reach the market. Additionally, the companies have developed multi-chamber prefilled syringes for use with lyophilised drugs. In our research, we have looked at how these developments and other factors are shaping the market and discussed the factors creating opportunities for various stakeholders in the market.

 

Scope of the Report

The ‘Prefilled Syringes Market’ report provides a comprehensive analysis of the state of prefilled syringes market. Starting with the basic introduction to prefilled syringes, their origin, components, and manufacturing material, this report talks about needlestick injuries and looks at the safety laws and legislations across major regional markets for injectable delivery. A key objective of the report is to enumerate various prefilled syringe systems available in the market, drugs available in these syringes and the corresponding market potential across different geographical regions. We have discussed various historical / likely future trends which have shaped / will shape the US, European, Japanese, Chinese and Rest of the World markets (such as India and Indonesia). We have also included a brief overview of biologics and biosimilars, one of the primary growth drivers of this market.

The study focuses on analysing the existing market size and potential future growth of these drug delivery devices across different drug therapeutic classes and regions. The forecast, over the next ten years, has been presented both in terms of volume (number of units) and value (USD billion). It takes into account the likely price variation which will occur as a result of mass adoption and increased competition. Owing to uncertainty surrounding the adoption of prefilled syringes in newer drug classes (which are currently in pipeline), we have done a multi-variate sensitivity analysis to understand the range of market growth scenarios.

In an effort to identify existing gaps and future opportunities, we have discussed the leading global prefilled syringe manufacturers in the industry, analysed their product portfolio and the likely future developments driven by these companies. We have also put emphasis and provided details on local manufacturers which are very well positioned to take advantage of the emerging home consumer markets.

The market forecasts across different segments and regions have been presented till 2024. 2013 is the base year; actual figures have been sourced and analysed from publicly available information. Unless otherwise specified, all figures are presented in USD.

Contents

Chapter 2  provides an executive summary of the insights captured in our research. The summary offers a high level view on the likely evolution of prefilled syringes market.

Chapter 3  provides a general overview of prefilled syringes including their origin, components, types, and manufacturing material. We have also listed the major prefilled syringes available and presented a high level market landscape.

Chapter 4  highlightsthe key growth drivers of prefilled syringes market. These include the growing trend of self-injection, rise in chronic diseases, changing patient demographics and growth of biologics. The chapter also talks about needlestick injuries and various preventive laws worldwide which have put the focus on safety features in prefilled syringes.

Chapter 5  highlights the leading therapeutic drug classes available in prefilled syringes. Also provided is a list of top ten drugs in prefilled syringes with three case studies. For each therapeutic class, we have identified the drugs available in prefilled syringes and estimated patent expiry; we have also looked at the biosimilars currently in development.

Chapter 6  details the technological developments in prefilled syringes market focusing on syringes being manufactured for lyophilised drugs.

Chapter 7  provides profiles of the key manufacturers of prefilled syringes. Each company profile includes information on financial performance, geographical presence, marketed devices, role and strategy for manufactured devices and recent developments.

Chapter 8  highlights the regional prefilled syringe manufacturers; we have briefly profiled the key players in Chinese, Japanese and Indian markets.

Chapter 9  provides the SWOT analysis of prefilled syringes market giving strategic insights in to the major factors that have contributed to the growth of the market, while highlighting the weaknesses and threats that can negatively impact the growth.

Chapter 10  analyses the regional markets (the US, Europe, Japan, China and RoW) for prefilled syringes. Within each region, the chapter focuses on the market size and various technological, commercial and regulatory details

Chapter 11  provides a detailed description of the likely evolution of prefilled syringes market. We have adopted a ‘bottom-up’ approach to identify the likely size of the market, both in terms of volume (number of units, in billions) and value (in USD billion).

Chapter 12  is a collection of interview transcripts. For the purposes of our study, we contacted a number of stakeholders in order to ascertain the key strategic initiatives and future roadmap of the industry.

Chapter 13  summarises the overall report. In this chapter, we provide a recap of the key takeaways and our independent opinion based on the research and analysis described in previous chapters.

Chapter 14  is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 15  is an appendix, which provides a list of companies and organisations mentioned in this report.

Table of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
 
2. EXECUTIVE SUMMARY
 
3. INTRODUCTION TO PREFILLED SYRINGES
3.1. What are Prefilled Syringes?
3.2. History of Prefilled Syringes
3.3. Benefits of Prefilled Syringes over Traditional Injectable Devices
3.3.1. Benefits for Healthcare Professionals and End Users
3.3.2. Benefits for Manufacturers
3.3.3. Shift of Existing Formulations to PFS
3.4. Prefilled Syringe Components
3.5. Classification of Prefilled Syringes
3.5.1. Manufacturing Material of Barrel
3.5.1.1. Glass: Historical Material of Choice
3.5.1.2. Limitations of Glass Prefilled Syringes
3.5.1.3. Addressing the Limitations of Glass Prefilled Syringes
3.5.1.4. Advantages of Plastic Prefilled Syringes
3.5.1.5. Slow Adoption of Plastic Prefilled Syringes
3.5.1.6. Factors Likely to Drive the Use of Plastic Prefilled Syringes
3.5.2. Single-Chamber and Dual-Chamber
3.5.3. Type of Needle
3.5.4. Type of Processing
3.6. Prefilled Syringe Systems Available in the Market
3.7. Glass Prefilled Syringes
3.8. Plastic Prefilled Syringes
 
4. GROWTH DRIVERS
4.1. Increase in Number of Self-injecting Patients
4.2. Increase in Incidence of Chronic Diseases
4.3. Changing Patient Demographics
4.4. Growth of Biologics and Biosimilars
4.5. Changing Pharmaceutical Strategies Driving Demand for Prefilled Syringes
4.6. Auto-Injectors / Pen-Injectors
4.6.1. Convergence of Prefilled Syringes with Autoinjectors
4.6.2. Pen Injectors vs. Autoinjectors
4.7. Needlestick Injuries and Safety Systems
4.7.1. Incidence and Cost Burden
4.7.2. Government Legislation for Needlestick Injury Prevention
4.7.3. Safety Mechanism Used by Prefilled Syringe Manufacturers
4.7.3.1. Unifill Safety Syringes
4.7.3.2. MedPro Prefilled Safety Syringes
4.7.3.3. Fulject Safety Syringes
4.7.3.4. LyoTwist Dual-Chambered Pen-Injector
 
5. PRODUCTS AVAILABLE IN PREFILLED SYRINGES
5.1. Drugs Approved in Prefilled Format in 2013-2014
5.2. Leading Drugs (By Sales) in Prefilled Format, 2013
5.2.1. Case Study: Humira (Adalimumab), AbbVie /Eisai
5.2.1.1. Indications and Dosage Forms
5.2.1.2. Humira: Launched in Prefilled Syringe
5.2.2. Case Study: Enbrel (Etanercept), Amgen/Pfizer/Takeda
5.2.2.1. Indications and Dosage Forms
5.2.2.2. Enbrel: Move from Vial to Syringes
5.2.3. Copaxone (Glatiramer acetate), Teva Pharmaceuticals
5.2.3.1. Indications and Dosage Forms
5.2.3.2. Copaxone: Move from Vial to Syringes
5.3. Other Drugs Available in Prefilled Format, 2014
5.4. Pipeline Products, 2014
5.5. Drugs Available by Therapeutic Classes, 2014
5.5.1. Anti-rheumatics
5.5.1.1. Approved Injectables
5.5.1.2. Biosimilars Anti-rheumatics
5.5.2. Multiple Sclerosis (MS)
5.5.2.1. Approved Injectables
5.5.2.2. Biosimilars Multiple Sclerosis
5.5.3. Anticoagulants
5.5.3.1. Approved Injectables
5.5.3.2. Biosimilars/Generics Anticoagulants
5.5.4. Anti-virals
5.5.4.1. Approved Injectables
5.5.4.2. Biosimilars Anti-virals
5.5.5. Anti-Diabetes Market
5.5.5.1. Anti-diabetic Drugs Available in Prefilled Syringes
5.5.6. Vaccines Market
5.6. Contrast Agents Available in Prefilled Syringes
 
6. TECHNOLOGICAL DEVELOPMENT IN PREFILLED SYRINGES
6.1. Chapter Overview
6.2. Prefilled Syringes for Lyophilised Drugs
6.2.1. Prefilled Diluent Syringes
6.2.2. Lyophilised Drugs Available in Prefilled Diluent Syringe Systems
6.2.3. Dual/Multi-Chamber Syringes
6.2.4. Lyophilised Drugs Available in Dual/Multi-Chamber Prefilled Syringe
6.2.5. Prefilled Dual-Chambered Pen Injectors for Lyophilised Drugs
6.2.6. Prefilled Reconstitution Systems for Lyophilised Drugs
 
7. LEADING GLOBAL PREFILLED SYRINGE MANUFACTURERS
7.1. Chapter Overview
7.2. Becton Dickinson (BD)
7.2.1. Company Overview
7.2.2. Financial Performance, 2013
7.2.3. Glass Prefilled Systems
7.2.3.1. BD Hypak Syringe System
7.2.3.2. BD Neopak Syringe System
7.2.4. Plastic Prefilled Systems
7.2.4.1. BD Sterifill Syringe Systems
7.2.5. Auto-injectors / Pen-injectors
7.2.5.1. BD Uniject
7.2.5.2. BD Physioject
7.2.6. Other Devices
7.2.7. Other Prefilled Delivery Systems
7.2.8. Safety Systems: Add-On Devices
7.2.9. BD Prefilled Technology Solutions
7.2.10. Recent Developments
7.2.10.1. Deals and Agreements
7.2.10.2. Expanding Prefilled Syringe Portfolio
7.2.10.3. Entering the Generic Business
7.2.10.4. Expanding the Safety Device Portfolio
7.2.11. Development Pipeline
 
7.3. Gerresheimer
7.3.1. Company Overview
7.3.2. Financial Performance, 2013
7.3.3. Glass Prefilled Systems
7.3.3.1. Gx Glass Syringes
7.3.4. Plastic Prefilled Systems
7.3.4.1. ClearJect Plastic Syringes
7.3.5. Safety Systems: Add-On Devices
7.3.6. Insulin Pens
7.3.7. Finishing Processes
7.3.8. Recent Developments
7.3.8.1. Expansion of Product Portfolio
7.3.8.2. Expansion of Manufacturing Capacity for RTF Syringes
7.3.8.3. Medical Plastic Systems Capacity Expansion
7.3.8.4. Growing Interest in Emerging Economies
 
7.4. Nipro Corporation (acquired MGlas AG)
7.4.1. Company Overview
7.4.2. Financial Performance, 2013
7.4.3. Glass Prefilled Systems
7.4.4. Recent Developments
7.4.4.1. Acquisition of MGlas AG
 
7.5. SCHOTT
7.5.1. Company Overview
7.5.2. Financial Performance, 2013
7.5.3. Glass Prefilled Systems
7.5.3.1. syriQ (previously Forma 3s) Glass Syringes
7.5.3.2. syriQ InJentle Syringes
7.5.4. Plastic Prefilled Systems
7.5.4.1. TopPac Polymer Syringes
7.5.5. Recent Developments
7.5.5.1. TopPac Syringe System for Highly Viscous Drugs
7.5.5.2. TopPac 20 ml Syringe System for Infusion Therapy
7.5.5.3. Rebranding of the Glass PFS
7.5.5.4. Looking To Grow in the Pharmerging Markets (Brazil, China, India, Indonesia, and Russia)
7.5.5.5. Production Facility in the US and EU Likely to Provide Advantage
 
7.6. Nuova Ompi
7.6.1. Company Overview
7.6.2. Glass Prefilled Systems
7.6.2.1. EZ-fill Syringes
7.6.3. Recent Developments
7.6.3.1. New Corporate Branding
7.6.3.2. Capacity Expansion Across the Glass Division
 
7.7. Other Prefilled Syringe Manufacturers
7.7.1. West Pharmaceutical Services
7.7.1.1. Company Overview
7.7.1.2. Financial Performance, 2013
7.7.1.3. Plastic Prefilled Systems
7.7.1.4. Autoinjectors and Other Systems
7.7.1.5. Safety Systems: Add-On Devices
7.7.1.6. Prefilled Technology Solutions
7.7.1.7. Syringe Components
7.7.1.8. Recent Developments
7.7.1.9. Development Pipeline
7.7.2. Unilife Corporation
7.7.2.1. Company Overview
7.7.2.2. Financial Performance, 2013
7.7.2.3. Glass Prefilled Systems
7.7.2.4. Autoinjectors
7.7.2.5. Wearable Injector Platform
7.7.2.6. Ocular Delivery Systems
7.7.2.7. Novel Delivery Systems
7.7.2.8. Recent Developments
 
7.7.3. Vetter Pharma
7.7.3.1. Company Overview
7.7.3.2. Lyo-Ject Glass Prefilled Systems
7.7.3.3. Safety Systems: Add on Devices
7.7.3.4. Recent Developments
 
8. REGIONAL PREFILLED SYRINGE MANUFACTURERS
8.1. Chinese Prefilled Syringe Manufacturers
8.1.1. Shandong Weigao Group Pharmaceutical Packaging Company Ltd.
8.1.2. Shandong Zibo Minkang Pharmaceutical Packing Co., Ltd.
8.1.3. Shandong Pharmaceutical Glass Co., Ltd.
8.1.4. YangZhong Wealth Metal Co., Ltd.
8.1.5. Youlyy Industrial Co., Ltd.
 
8.2. Japanese Prefilled Syringe Manufacturers
8.2.1. Terumo Corporation
8.2.1.1. Company Overview
8.2.1.2. Financial Performance, 2013
8.2.1.3. Plajex: Plastic Prefilled Systems
8.2.1.4. Safety Devices: Add-On Devices
8.2.2. Taisei Kako Co., Ltd.
8.2.2.1. Company Overview
8.2.2.2. VF-Syringe Glass Prefilled Syringes
8.2.2.3. ClearJect Plastic Prefilled Syringes
8.2.2.4. Fulject Plastic Prefilled Syringes
8.2.3. ARTE CORPORATION
8.2.3.1. Company Overview
8.2.3.2. Arte Prefillable Syringes
8.2.4. J.O. Pharma Co., Ltd. (subsidiary of Otsuka Holdings Co., Ltd)
 
8.3. Indian Prefilled Syringe Manufacturers
8.3.1. Roselabs Group
8.3.1.1. Company Overview
8.3.1.2. Glass Prefilled Systems
8.3.1.3. Plastic Prefilled Systems
8.3.1.4. Recent Developments
 
9. SWOT ANALYSIS
9.1. Overview
9.2. Strengths
9.3. Weaknesses
9.4. Opportunities
9.5. Threats
 
10. LEADING REGIONAL MARKETS FOR PREFILLED SYRINGE SYSTEMS, 2014 - 2024
10.1. The US Market for Prefilled Syringes, 2014
10.1.1. Prefilled Syringes are Combination Products
10.1.1.1. Regulation of Combination Products in the US
10.1.1.2. Regulatory Approval of Prefilled Syringes in the US
10.1.2. Trends in the US Prefilled Syringes Market
 
10.2. European Market for Prefilled Syringes, 2014
10.2.1. Combination Products in Europe
10.2.2. Regulatory Approval of Prefilled Syringes in Europe
10.2.3. Trends in the European Prefilled Syringe Market
10.2.3.1. Europe is the Preferred Destination for Manufacturing Prefilled Syringes
 
10.3. The Chinese Market for Prefilled Syringes, 2014
10.4. Rest of the World Markets for Prefilled Syringes, 2014
10.4.1. The Japanese Market for Prefilled Syringes
10.4.1.1. Regulation of Combination Products in Japan
10.4.1.2. Primary Pharmaceutical Packaging Market in Japan
10.4.1.3. State of the Market: Drugs and Companies
10.4.2. Indian Market for Prefilled Syringes, 2013
10.4.3. Indonesian Market for Prefilled Syringes, 2014
 
11. GLOBAL PREFILLED SYRINGES MARKET FORECAST, 2014 - 2024
11.1. Background
11.2. Scope and Methodology
11.3. Global Market Size and Forecast
11.3.1. Prefilled Syringes for Vaccines
11.3.2. Prefilled Syringes for Drugs
11.3.2.1. Prefilled Syringes for Anticoagulants
11.3.2.2. Prefilled Syringes for Diabetes
11.3.2.3. Prefilled Syringes for Multiple Sclerosis Drugs
11.3.2.4. Prefilled Syringes for Anti-Arthritic Drugs
11.3.2.5. Prefilled Syringes for Anti-Anaemic Drugs
11.3.2.6. Prefilled Syringes for Other Drug Classes
11.3.3. Prefilled Diluent Syringes, Prefilled Flush Syringes and Prefilled Syringes for Contrast Agents
11.3.4. Overall Global Market Size
11.4. Regional Market Size and Forecast: US, Europe, China and Rest of the World
 
12. INTERVIEW TRANSCRIPTS
 
13. CONCLUSION
13.1. The Shift from Vials to Prefilled Syringes
13.2. Plastic Syringes to Outperform Glass Syringes
13.3. Consolidated Market with Five Established Players; New Entrants Driving Innovation
13.4. Growth of Biologics, Rising Trend of Self-Medication and Many Other Factors will Fuel the Growth
13.5. Double-Digit Growth Expected to Continue Over the Coming Decade
13.6. Despite Being Full of Opportunities, Challenges Remain
 
14. APPENDIX 1: TABULATED DATA
 
15. APPENDIX 2: LIST OF COMPANIES AND ORGANISATIONS

List of Figures

Figure 2.1  Market Evolution: 2013, 2019, 2024 (Number of Units)
Figure 2.2  Market Landscape: Geographical Trends
Figure 3.1  Prefilled Syringes: Market Landsacpe by Manufacturer
Figure 4.1  Global Prevalence of Diabetes: Distribution by Countries, 2013 (Million, %)
Figure 4.2  Numbers of Biologics Approved by the USFDA, 2009-2013
Figure 5.1  Sales of Leading Drugs Available in Prefilled Syringes, 2013 (USD Million)
Figure 5.2  Humira Global Sales, 2003-2013 (USD Million)
Figure 5.3  Enbrel US Sales, 2002-2013 (USD Million)
Figure 5.4  Copaxone Sales, 2001-2013 (USD Million)
Figure 5.5  Copaxone Unit Sales, 2000-2008: Distribution by Vials and Prefilled Syringes (Million)
Figure 5.6  Numbers of Biosimilars in Development for Anti-Rheumatics
Figure 5.7  Numbers of Biosimilars in Development for Multiple Sclerosis Drugs
Figure 5.8  Numbers of Biosimilars in Development for Anticoagulants
Figure 5.9  Numbers of Biosimilars in Development for Anti-Virals
Figure 7.1  Becton Dickinson Medical, 2013: Sales by Business Divisions (USD Million, %)
Figure 7.2   Gerresheimer, 2013: Sales by Business Divisions (EUR Million, %)
Figure 7.3 Nipro Corporation: Sales by Business Divisions, 2013 (YEN Billion, %)
Figure 7.4  SCHOTT: Sales by Business Divisions, 2013 (EUR Million, %)
Figure 7.5  West Pharmaceutical Services: Sales by Business Divisions, 2013 (USD Million, %)
Figure 7.6  Unilife Corporation: Sales, FY 2011 - FY 2013 (USD ‘000)
Figure 8.1  Domestic Prefilled Syringe Manufacturers in China: Annual Production Capacities, 2012 (Million Units)
Figure 8.2  Shandong Weigao: Prefilled Syringes Revenue (RMB Million), 2009-2013
Figure 8.3  Terumo Corporation: Sales by Business Divisions, 2013 (YEN Billion, %)
Figure 9.1  Common Medication Errors (%)
Figure 9.2  Common Sources of Medication Errors (%)
Figure 9.3  Prefilled Syringe Recalls, 2002-2014: By Type of Issue
Figure 10.1 The US Vaccines Market: By Type of Packaging (%)
Figure 10.2  European Vaccines Market: By Type of Packaging (%)
Figure 10.3  Japanese Prefilled Syringes Market: By Material of Barrel (%)
Figure 11.1  Prefilled Syringes Price Curve, 2014 – 2024 (USD per unit)
Figure 11.2  Prefilled Syringes for Vaccines, Forecasted Number of Units, 2014 - 2024 (Base Scenario, Millions)
Figure 11.3  Prefilled Syringes for Vaccines, Forecast Sales, 2014 - 2024 (Base Scenario, USD Million)
Figure 11.4  Prefilled Syringes for Anticoagulants, Forecasted Number of Units, 2014 - 2024 (Base Scenario, Millions)
Figure 11.5  Prefilled Syringes for Anticoagulants, Forecast Sales, 2014 - 2024 (Base Scenario, USD Million)
Figure 11.6  Prefilled Syringes for Diabetes, Forecasted Number of Units, 2014 - 2024 (Base Scenario, Millions)
Figure 11.7  Prefilled Syringes for Diabetes, Forecast Sales, 2014 - 2024 (Base Scenario, USD Million)
Figure 11.8  Prefilled Syringes for Multiple Sclerosis Drugs, Forecasted Number of Units, 2014 - 2024 (Base Scenario, Millions)
Figure 11.9  Prefilled Syringes for Multiple Sclerosis Drugs, Forecast Sales, 2014 - 2024 (Base Scenario, USD Million)
Figure 11.10  Prefilled Syringes for Anti-Arthritic Drugs, Forecasted Number of Units, 2014 - 2024 (Base Scenario, Millions)
Figure 11.11  Prefilled Syringes for Anti-Arthritic Drugs, Forecast Sales, 2014 - 2024 (Base Scenario, USD Million)
Figure 11.12  Prefilled Syringes for Anti-Anaemic Drugs, Forecasted Number of Units, 2014 - 2024 (Base Scenario, Millions)
Figure 11.13  Prefilled Syringes for Anti-Anaemic Drugs, Forecast Sales, 2014 - 2024 (Base Scenario, USD Million)
Figure 11.14  Prefilled Syringes for Other Drug Classes, Forecasted Number of Units, 2014 - 2024 (Base Scenario, Millions)
Figure 11.15  Prefilled Syringes for Other Drug Classes, Forecast Sales, 2014 - 2024 (Base Scenario, USD Million)
Figure 11.16  Prefilled Diluent Syringes, Flush Syringes and Prefilled Syringes for Contrast Agents, Forecasted Number of Units, 2014 - 2024 (Base Scenario, Millions)
Figure 11.17  Prefilled Diluent Syringes, Flush Syringes and Prefilled Syringes for Contrast Agents, Forecast Sales, 2014 - 2024 (Base Scenario, USD Million)
Figure 11.18  Global Prefilled Syringes, Forecast Number of Units, 2014 - 2024 (Base Scenario, Millions)
Figure 11.19  Global Prefilled Syringes, Units Growth by Category, 2014 - 2024 (Base Scenario, USD Million)
Figure 11.20  Global Prefilled Syringes, Sales Forecast, 2014 - 2024 (Base Scenario, USD Million)
Figure 11.21  Global Prefilled Syringes, Sales Growth by Category, 2014 - 2024 (Base Scenario, USD Million)
Figure 11.22  Regional Prefilled Syringes, Forecast Number of Units, 2014 - 2024 (Base Scenario, Millions)
Figure 11.23  Regional Prefilled Syringes, Sales Forecast, 2014 - 2024 (Base Scenario, USD Million)
Figure 11.24  Prefilled Syringes Market, Distribution by Regions, 2013 - 2024 (%)
Figure 13.1  Prefilled Syringes Market: 2014, 2019 and 2024 (Units, Billions)
Figure 13.2  Prefilled Syringes Market: 2014, 2019, 2024 (USD Billion)

List of Tables

Table 3.1  List of Drugs which Shifted Their Presentation to Prefilled Syringe Systems in the US
Table 3.2  Classification of Prefilled Syringes
Table 3.3  Advantages of Glass as Barrel Material
Table 3.4  Prefilled Glass Syringe Recalls
Table 3.5  Advantages of Plastic Polymers as Barrel Material
Table 3.6  Pharmaceutical Filling Lines - Process Flow by Type of Prefilled Syringe
Table 3.7  Prefilled Syringe Systems Available in the Market, 2014: A Comparison, By Manufacturer
Table 3.8  Glass Prefilled Syringes Available in the Market, 2014
Table 3.9  Plastic Prefilled Syringes Available in the Market, 2014
Table 4.1  Population Over 65 in the US and Selected Countries in Europe, 2010, 2015 and 2020 (%)
Table 4.2  List of Auto-injector/Pen-injector Systems - Approved in 2013-2014
Table 4.3  List of Auto-injector/Pen-injector Systems (Using Prefilled Syringes) Available in the Market
Table 4.4  List of Safety Device Manufacturers
Table 5.1  Drugs Approved in Prefilled Syringes, 2013-2014
Table 5.2  List of Other Drugs Sold in Prefilled Syringes
Table 5.3  List of Pipeline Drugs Using Prefilled Syringe Systems,
Table 5.4  Anti-rheumatics (Injectables) Sales, 2013: Distribution by Leading Drugs (USD Million, %)
Table 5.5  Anti-rheumatics (Injectables) Drugs Available in Prefilled Syringes, 2014
Table 5.6  Anti-rheumatic Drugs (Injectables) Available in Prefilled Format: Patent Expiry and Biosimilar Development
Table 5.7  Multiple Sclerosis (Injectables) Sales, 2013: Distribution by Leading Drugs (USD Million, %)
Table 5.8  Multiple Sclerosis Drugs (Injectables) Available in Prefilled Syringes, 2014
Table 5.9  Multiple Sclerosis Drugs (Injectables) available in Prefilled Format: Patent Expiry and Biosimilar Development
Table 5.10  Anticoagulants Sales (Injectables), 2013: Distribution by Leading Drugs (USD Million, %)
Table 5.11  Anticoagulants (Injectables) Available in Prefilled Syringes, 2014
Table 5.12  Anticoagulants (Injectables) available in Prefilled Format:  Patent Expiry and Biosimilars/Generics Development
Table 5.13  Anti-virals (Injectables) Sales, 2013: Distribution by Leading Drugs (USD Million, %)
Table 5.14  Anti-virals (Injectables) Available in Prefilled Syringes, 2014
Table 5.15  Anti-virals (Injectables) available in Prefilled Format: Patent Expiry and Biosimilar Development
Table 5.16  Anti-Diabetes Market: Distribution by Leading Drugs (USD Million, %)
Table 5.17  Vaccines (Injectables) Sales, 2013: Distribution by Leading Vaccines (USD Million, %)
Table 5.18  Leading Vaccines (Injectables) Available in Prefilled Syringes, 2014
Table 5.19  Contrast Agents Available in Prefilled Syringes, 2014
Table 6.1  Drugs Marketed in Prefilled Diluent Syringes
Table 6.2  Prefilled Syringes for Lyophilised Drugs
Table 6.3  Drugs Marketed in Dual/Multi-Chamber Prefilled Syringes
Table 7.1    Features of Gx Glass Prefilled Syringe
Table 7.2  Features of ClearJect Prefilled Syringe
Table 7.3  Features of syriQ Prefilled Syringe
Table 7.4  Features of syriQ Injentle Prefilled Syringe
Table 7.5  Features of TopPac Prefilled Syringe
Table 7.6  Features of EZ-Fill Prefilled Syringe
Table 7.7  Features of Daikyo CZ Prefilled Syringe
Table 8.1  Domestic Prefilled Syringe Manufacturers in China: Comparison of Product Portfolio
Table 9.1  SWOT Analysis
Table 9.2  Prefilled Syringe Recalls, 2003-2014
Table 9.3  List of Marketed/Pipeline Needleless Injection Devices
Table 10.1 Seasonal Flu Vaccines in the US, 2013-2014
Table 10.2  Drugs Approved in Prefilled Syringes Format in Japan
Table 11.1 Prefilled Syringes Price Estimate (USD per unit)
Table 11.2  Vaccines Administered Via Prefilled Syringes
Table 11.3  List of Anticoagulants and Administration Route
Table 11.4  List of Anticoagulants Sold in Prefilled Syringes
Table 11.5  List of Multiple Sclerosis Drugs and Administration Route
Table 11.6  List of Multiple Sclerosis Drugs Sold in Prefilled Syringes
Table 11.7  List of Anti-Arthritic Drugs and Administration Route
Table 11.8  List of Anti-Arthritic Drugs Sold in Prefilled Syringes
Table 11.9  List of Anti-Anaemic Drugs and Administration Route
Table 11.10 List of Anti-Anaemic Drugs Sold in Prefilled Syringes
Table 11.11  List of Other Drugs Sold in Prefilled Syringes
Table 11.12  List of Contrast Agents using Prefilled Syringes
Table 14.1  Sales of Leading Drugs Available in Prefilled Syringes, 2013 (USD Million)
Table 14.2  Humira Global Sales, 2003-2013 (USD Million)
Table 14.3  Enbrel US Sales, 2002-2013 (USD Million)
Table 14.4  Copaxone Sales, 2001-2013 (USD Million)
Table 14.5  Copaxone Unit Sales, 2000-2008: By Vials and Prefilled Syringes (Million)
Table 14.6  Becton Dickinson Medical, 2013 - Sales by Business Divisions (USD Million, %)
Table 14.7  Gerresheimer, 2013 - Sales by Business Divisions (EUR Million, %)
Table 14.8  Nipro Corporation, 2013 - Sales by Business Divisions (YEN Billion, %)
Table 14.9  SCHOTT, 2013 - Sales by Business Divisions (EUR Million, %)
Table 14.10  West Pharmaceutical Services, 2013 - Sales by Business Divisions (USD Million, %)
Table 14.11  Unilife Corporation, Sales FY 2011 – FY 2013 (USD ‘000)
Table 14.12  Domestic Prefilled Syringe Manufacturers in China - Annual Production Capacities, 2012 (Million Units)
Table 14.13  Shandong Weigao: Revenue from Prefilled Syringes (RMB Million), 2009-2013
Table 14.14  Terumo Corporation, 2013: Sales by Business Divisions (YEN Billion, %)
Table 14.15  Prefilled Syringes Price Curve, 2014 – 2024 (USD per unit)
Table 14.16  Prefilled Syringes for Vaccines, Forecasted Number of Units, 2014 - 2024 (Base Scenario, Millions)
Table 14.17  Prefilled Syringes for Vaccines, Forecasted Number of Units, 2014 - 2024 (Conservative Scenario, Millions)
Table 14.18  Prefilled Syringes for Vaccines, Forecasted Number of Units, 2014 - 2024 (Optimistic Scenario, Millions)
Table 14.19  Prefilled Syringes for Vaccines, Forecast Sales, 2014 - 2024 (Base Scenario, USD Million)
Table 14.20  Prefilled Syringes for Vaccines, Forecast Sales, 2014 - 2024 (Conservative Scenario, USD Million)
Table 14.21  Prefilled Syringes for Vaccines, Forecast Sales, 2014 - 2024 (Optimistic Scenario, USD Million)
Table 14.22  Prefilled Syringes for Anticoagulants, Forecasted Number of Units, 2014 - 2024 (Base Scenario, Millions)
Table 14.23  Prefilled Syringes for Anticoagulants, Forecasted Number of Units, 2014 - 2024 (Conservative Scenario, Millions)
Table 14.24  Prefilled Syringes for Anticoagulants, Forecasted Number of Units, 2014 - 2024 (Optimistic Scenario, Millions)
Table 14.25  Prefilled Syringes for Anticoagulants, Forecast Sales, 2014 - 2024 (Base Scenario, USD Million)
Table 14.26  Prefilled Syringes for Anticoagulants, Forecast Sales, 2014 - 2024 (Conservative Scenario, USD Million)
Table 14.27  Prefilled Syringes for Anticoagulants, Forecast Sales, 2014 - 2024 (Optimistic Scenario, USD Million)
Table 14.28  Prefilled Syringes for Diabetes, Forecasted Number of Units, 2014 - 2024 (Base Scenario, Millions)
Table 14.29  Prefilled Syringes for Diabetes, Forecasted Number of Units, 2014 - 2024 (Conservative Scenario, Millions)
Table 14.30  Prefilled Syringes for Diabetes, Forecasted Number of Units, 2014 - 2024 (Optimistic Scenario, Millions)
Table 14.31  Prefilled Syringes for Diabetes, Forecast Sales, 2014 - 2024 (Base Scenario, USD Million)
Table 14.32  Prefilled Syringes for Diabetes, Forecast Sales, 2014 - 2024 (Conservative Scenario, USD Million)
Table 14.33  Prefilled Syringes for Diabetes, Forecast Sales, 2014 - 2024 (Optimistic Scenario, USD Million)
Table 14.34  Prefilled Syringes for Multiple Sclerosis Drugs, Forecasted Number of Units, 2014 - 2024 (Base Scenario, Millions)
Table 14.35  Prefilled Syringes for Multiple Sclerosis Drugs, Forecasted Number of Units, 2014 - 2024 (Conservative Scenario, Millions)
Table 14.36  Prefilled Syringes for Multiple Sclerosis Drugs, Forecasted Number of Units, 2014 - 2024 (Optimistic Scenario, Millions)
Table 14.37  Prefilled Syringes for Multiple Sclerosis Drugs, Forecast Sales, 2014 - 2024 (Base Scenario, USD Million)
Table 14.38  Prefilled Syringes for Multiple Sclerosis Drugs, Forecast Sales, 2014 - 2024 (Conservative Scenario, USD Million)
Table 14.39  Prefilled Syringes for Multiple Sclerosis Drugs, Forecast Sales, 2014 - 2024 (Optimistic Scenario, USD Million)
Table 14.40  Prefilled Syringes for Anti-Arthritic Drugs, Forecasted Number of Units, 2014 - 2024 (Base Scenario, Millions)
Table 14.41  Prefilled Syringes for Anti-Arthritic Drugs, Forecasted Number of Units, 2014 - 2024 (Conservative Scenario, Millions)
Table 14.42  Prefilled Syringes for Anti-Arthritic Drugs, Forecasted Number of Units, 2014 - 2024 (Optimistic Scenario, Millions)
Table 14.43  Prefilled Syringes for Anti-Arthritic Drugs, Forecast Sales, 2014 - 2024 (Base Scenario, USD Million)
Table 14.44  Prefilled Syringes for Anti-Arthritic Drugs, Forecast Sales, 2014 - 2024 (Conservative Scenario, USD Million)
Table 14.45  Prefilled Syringes for Anti-Arthritic Drugs, Forecast Sales, 2014 - 2024 (Optimistic Scenario, USD Million)
Table 14.46  Prefilled Syringes for Anti-Anaemic Drugs, Forecasted Number of Units, 2014 - 2024 (Base Scenario, Millions)
Table 14.47  Prefilled Syringes for Anti-Anaemic Drugs, Forecasted Number of Units, 2014 - 2024 (Conservative Scenario, Millions)
Table 14.48  Prefilled Syringes for Anti-Anaemic Drugs, Forecasted Number of Units, 2014 - 2024 (Optimistic Scenario, Millions)
Table 14.49  Prefilled Syringes for Anti-Anaemic Drugs, Forecast Sales, 2014 - 2024 (Base Scenario, USD Million)
Table 14.50  Prefilled Syringes for Anti-Anaemic Drugs, Forecast Sales, 2014 - 2024 (Conservative Scenario, USD Million)
Table 14.51  Prefilled Syringes for Anti-Anaemic Drugs, Forecast Sales, 2014 - 2024 (Optimistic Scenario, USD Million)
Table 14.52  Prefilled Syringes for Other Drug Classes, Forecasted Number of Units, 2014 - 2024 (Base Scenario, Millions)
Table 14.53  Prefilled Syringes for Other Drug Classes, Forecasted Number of Units, 2014 - 2024 (Conservative Scenario, Millions)
Table 14.54  Prefilled Syringes for Other Drug Classes, Forecasted Number of Units, 2014 - 2024 (Optimistic Scenario, Millions)
Table 14.55  Prefilled Syringes for Other Drug Classes, Forecast Sales, 2014 - 2024 (Base Scenario, USD Million)
Table 14.56  Prefilled Syringes for Other Drug Classes, Forecast Sales, 2014 - 2024 (Conservative Scenario, USD Million)
Table 14.57  Prefilled Syringes for Other Drug Classes, Forecast Sales, 2014 - 2024 (Optimistic Scenario, USD Million)
Table 14.58  Prefilled Diluent Syringes, Flush Syringes and Prefilled Syringes for Contrast Agents, Forecasted Number of Units, 2014 - 2024 (Base Scenario, Millions)
Table 14.59  Prefilled Diluent Syringes, Flush Syringes and Prefilled Syringes for Contrast Agents, Forecasted Number of Units, 2014 - 2024 (Conservative Scenario, Millions)
Table 14.60  Prefilled Diluent Syringes, Flush Syringes and Prefilled Syringes for Contrast Agents, Forecasted Number of Units, 2014 - 2024 (Optimistic Scenario, Millions)
Table 14.61  Prefilled Diluent Syringes, Flush Syringes and Prefilled Syringes for Contrast Agents, Forecast Sales, 2014 - 2024 (Base Scenario, USD Million)
Table 14.62  Prefilled Diluent Syringes, Flush Syringes and Prefilled Syringes for Contrast Agents, Forecast Sales, 2014 - 2024 (Conservative Scenario, USD Million)
Table 14.63  Prefilled Diluent Syringes, Flush Syringes and Prefilled Syringes for Contrast Agents, Forecast Sales, 2014 - 2024 (Optimistic Scenario, USD Million)
Table 14.64  Regional Prefilled Syringes, Forecast Number of Units, 2014 - 2024 (Base Scenario, Millions)
Table 14.65  Regional Prefilled Syringes, Forecast Number of Units, 2014 - 2024 (Conservative Scenario, Millions)
Table 14.66  Regional Prefilled Syringes, Forecast Number of Units, 2014 - 2024 (Optimistic Scenario, Millions)
Table 14.67  Regional Prefilled Syringes, Sales Forecast 2014 - 2024 (Base Scenario, USD Million)
Table 14.68  Regional Prefilled Syringes, Sales Forecast 2014 - 2024 (Conservative Scenario, USD Million)
Table 14.69  Regional Prefilled Syringes, Sales Forecast 2014 - 2024 (Optimistic Scenario, USD Million)

Listed Companies

The following companies and organisations have been mentioned in this report

  1. Abbott Laboratories
  2. Abbvie Biotherapeutics
  3. Adamis Pharmaceuticals Corporation
  4. Aguettant
  5. Akorn
  6. Al Biosciences Inc.
  7. Alchemia Limited
  8. Alfamatic
  9. Allergan
  10. Almirall
  11. American Nurses Association (ANA)
  12. Amgen
  13. Amphastar Pharmaceuticals
  14. Antares Pharma
  15. Aptar Pharm
  16. Arte Corporation
  17. Aspen Group
  18. AstraZeneca
  19. Avesthagen
  20. Bang and Olufsen
  21. BASF Bioresearch Corporation
  22. Baxter
  23. Bayer Healthcare
  24. BD Rx Inc.
  25. Beacon Pharmaceuticals Ltd.
  26. Becton Dickinson
  27. Bespak
  28. Bio Farma
  29. Biodel Inc.
  30. Biogen Idec
  31. Biogenomics
  32. Bioneer
  33. Bioxpress Therapeutics
  34. Boehringer Ingelheim Pharmaceuticals
  35. Bracco Diagnostics
  36. Bristol Myers Squibb
  37. Buender Glas
  38. Cadilla Healthcare
  39. Cambridge Antibody Technology(Acquired by AstraZeneca)
  40. Cambridge Consultants
  41. Canyon Pharmaceuticals
  42. Celltrion
  43. Chon Kun Dang Pharmaceuticals
  44. Chugai Pharmaceutical Co., Ltd.
  45. Cipla
  46. CNS Therapeutics (acquired by Mallinckrodt)
  47. Coherus Biosciences
  48. Covidien
  49. CP Guojian Pharmaceutical Co. Ltd
  50. CSL Biotherapies
  51. Daicel Corporation
  52. Daikyo Seiko
  53. Denka Seiken Co., Ltd.
  54. Dr. Reddy's Laboratories
  55. Eisai
  56. Elan Pharmaceuticals
  57. Elcam Medical
  58. Eli Lilly
  59. Emcure
  60. EMD Serono
  61. Enzon Pharma
  62. European Agency of Occupational Safety and Health
  63. European Medicines Agency (EMA)
  64. European Medicines Evaluation Agency (EMEA)
  65. Eyetech Inc.
  66. FDA
  67. Fresenius Kabi
  68. GE Healthcare
  69. Genentech
  70. Gerresheimer
  71. GlaxoSmithKline
  72. Globe Medical Tech
  73. Green Cross
  74. Guerbet
  75. Halozyme Therapeutics
  76. Hanwha Chemical
  77. Haselmeier
  78. Helvoet Pharma
  79. Hikma Pharmaceuticals PLC
  80. Hoffman-La Roche
  81. Hospira
  82. ID Biomedical Corporation of Quebec
  83. Il-Yang Pharm. Co., Ltd
  84. Immunex Corporation
  85. Incepta Pharmaceuticals Ltd.
  86. Infusive Technologies LLC
  87. Intas Pharma
  88. Ipsen
  89. IVEK Corporation
  90. J&J
  91. J.O. Pharma Co. Ltd. 
  92. Janssen Biotech Inc.
  93. Japan Synthetic Rubber
  94. JCR Pharmaceuticals
  95. JMS Co. Ltd. 
  96. KAISHA Manufacturers
  97. Kaketsuken [The Chemo-Sero-Therapeutic Research Institute]
  98. Kaleo Inc.
  99. Kitasato Daiichi Sankyo Vaccine
  100. Kyowa Hakko Kirin
  101. Leo Pharma
  102. LG Life Sciences
  103. Liebmann Group
  104. LyoGo
  105. Mallinckrodt
  106. Marathon Pharmaceuticals
  107. Maruishi Pharmaceutical
  108. Medac Pharma
  109. Medical Glass
  110. MedImmune
  111. Medimop Medical Projects
  112. MedPro Safety Products
  113. Merck & Co.
  114. Meridian
  115. MGlas AG
  116. Minapharm Pharmaceuticals
  117. Mitsubishi Tanabe
  118. Mitsui Chemicals
  119. Momenta Pharmaceuticals
  120. MorphoSys
  121. MSD K.K.
  122. Mycenax Biotech Inc.
  123. Mylan
  124. Nanogen Biopharmaceuticals
  125. NATCO Pharma
  126. Nektar Therapeutics
  127. Neutral Glass & Allied industries
  128. Nippon Organon K.K.
  129. Nipro Corporation
  130. Novartis
  131. Novo Nordisk
  132. NPS Pharmaceuticals
  133. Nuova Ompi
  134. Occupational Safety and Health Administration (OSHA)
  135. Office of Combination Products (OCP)
  136. Onco Biologics Inc.
  137. Ono Pharmaceuticals
  138. Otsuka Holdings Co. Ltd.
  139. Owen Mumford
  140. PA Consulting
  141. Palatin Technologies
  142. Parenteral Drug Association
  143. Pfizer
  144. Pharmaceutical Research and Manufacturers of America (PhRMA)
  145. Pisa
  146. Plas-Tech
  147. ProJect  Pharmaceutics
  148. Protalix Biotherapeutics
  149. PT BioFarma
  150. Raumedic
  151. Regeneron Pharmaceuticals
  152. Rexam Pharma
  153. Rhône Poulenc-Rorer
  154. Roehr Products
  155. RoseLabs
  156. SafeShot Technologies
  157. Safety Syringes
  158. Samsung Bioepsis
  159. Sandoz
  160. Sanofi Aventis
  161. Sanofi Pasteur
  162. Schering-Plough
  163. Schott
  164. Sciele Pharma
  165. Serum Institute of India
  166. Shandong Pharmaceutical Glass Co., Ltd.
  167. Shandong Weigao
  168. Shandong Zibo Minkang Pharmaceutical Packing Co., Ltd.
  169. SHL Medical
  170. Stada Arzneimittel AG 
  171. Stelmi
  172. Stevanato Group
  173. Stiefel (a GSK Company)
  174. Strides
  175. Sun Pharma
  176. Suzuken Co. Ltd.
  177. Swedish Orphan Biovitrum AB
  178. Taisei Kako
  179. Taj Pharmaceuticals
  180. Takeda
  181. Talecris Biotherapeutics
  182. TechnoPharm
  183. Teijin Pharma Ltd.
  184. Terumo Corporation
  185. Teva Pharmaceuticals
  186. The Medical House
  187. The Medicines Company
  188. The Research Foundation for Microbial Diseases of Osaka University
  189. Ticona
  190. Tolmar
  191. TriboFilm Research
  192. Triveni Polymers
  193. Troikaa Pharma
  194. TSH Biopharm Corporation Ltd.
  195. UCB
  196. UNICEF
  197. Unilife Corporation
  198. USPTO
  199. Vedat
  200. Vetter Pharma
  201. Virchow Biotech Private Ltd.
  202. Watson Pharma
  203. West Pharmaceutical Services
  204. WHO
  205. Wyeth
  206. YangZhong Wealth Metal Co., Ltd.
  207. Youlyy Industrial Co., Ltd.
  208. Ypsomed
  209. Zeon Corporation
  210. Zhejiang Xinkang Pharmaceutical Glass Co. Ltd.
  211. ZymoGenetics Inc

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 1,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com